# MAGEC1

## Overview
MAGEC1, or Melanoma Antigen Family C1, is a gene that encodes a protein belonging to the cancer-testis antigen family, which is characterized by its restricted expression in normal tissues, primarily in the testis, and aberrant expression in various cancers. The MAGEC1 protein is involved in several cellular processes, including transcription regulation and protein-protein interactions, particularly in the context of tumorigenesis. It is known to interact with other cancer-testis antigens, such as CTAG1B/A, and components of the transcription machinery, suggesting a role in supporting transcriptional programs active in germ cells and tumors (Papanikolaou2022SystemsLevel). The gene's expression and mutations have been implicated in the progression and prognosis of multiple cancers, including hepatocellular carcinoma, multiple myeloma, prostate cancer, melanoma, and Müllerian adenosarcoma, making it a potential target for cancer immunotherapy (Ban2020WholeGenome; Caballero2009Cancertestis; Mattila2011NMD).

## Clinical Significance
MAGEC1 is implicated in several cancers due to its aberrant expression and mutations. In hepatocellular carcinoma, MAGEC1 expression is associated with reduced overall survival, indicating its potential role in tumor progression (Caballero2009Cancertestis). In multiple myeloma, MAGEC1 expression correlates with disease stage and risk status, suggesting its involvement in the disease's progression (Caballero2009Cancertestis).

In prostate cancer, a specific mutation in MAGEC1, p.Met1? (c.2T > C; Met > Thr), has been linked to an increased risk of hereditary prostate cancer (HPC) and unselected prostate cancer (PC) cases. This mutation shows a statistically significant association with prostate cancer, particularly when using certain control groups (Mattila2011NMD).

MAGEC1 mutations are also observed in melanoma, with a frequency of 16% in fresh melanoma samples, suggesting a role in tumorigenesis (Caballero2010Frequent). In Müllerian adenosarcoma, MAGEC1 mutations are present in 34% of cases, indicating its involvement in the genetic alterations associated with this tumor type (Ban2020WholeGenome). These findings highlight MAGEC1 as a potential target for cancer immunotherapy due to its restricted expression pattern and immunogenic properties.

## Interactions
MAGEC1, a member of the melanoma antigen family, is involved in various protein-protein interactions, particularly in the context of cancer-testis antigens. It is known to form intracellular complexes with CTAG1B/A, another cancer-testis antigen protein. This interaction is significant in synovial sarcoma cells, where MAGEC1 shows extensive positivity in some cases. The study by Papanikolaou et al. constructed a CTAG1B/A-centered sarcoma network, identifying MAGEC1 as a close neighbor in the sub-network, suggesting potential interactions with other proteins like PRAME, SIX1, and RANBP2 (Papanikolaou2022SystemsLevel).

MAGEC1 is also noted for its interaction with RNA polymerase II subunits, indicating a potential role in specialized transcription complexes in germ cells. This suggests that MAGEC1, along with CTAG1B/A and PRAME, may contribute to tumor biology by supporting transcription programs typically active in gametogenic germ cells (Papanikolaou2022SystemsLevel). The presence of transcription factors in the CTAG1B/A network supports the hypothesis that these complexes could be recruited to support tumor growth. However, specific details on the interactions of MAGEC1 with other proteins or nucleic acids beyond its association with CTAG1B/A are not provided in the available context (Papanikolaou2022SystemsLevel).


## References


[1. (Papanikolaou2022SystemsLevel) Nikolaos A. Papanikolaou, Prodromos Hytiroglou, Pavlina Pantelidou, Athanasios G. Papavassiliou, and Lloyd L. Old. Systems-level mapping of cancer testis antigen 1b/a to sarcoma pathways identifies activated ran binding-2 e3 sumo-protein ligase and transducin-like enhancer protein 1. Frontiers in Genetics, May 2022. URL: http://dx.doi.org/10.3389/fgene.2022.834445, doi:10.3389/fgene.2022.834445. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.834445)

[2. (Caballero2010Frequent) Otavia L. Caballero, Qi Zhao, Donata Rimoldi, Brian J. Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F. Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D. Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J. Van den Eynde, Lloyd J. Old, Xin Lu, Jonathan Cebon, Robert L. Strausberg, and Andrew J. Simpson. Frequent mage mutations in human melanoma. PLoS ONE, 5(9):e12773, September 2010. URL: http://dx.doi.org/10.1371/journal.pone.0012773, doi:10.1371/journal.pone.0012773. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0012773)

[3. (Caballero2009Cancertestis) Otavia L. Caballero and Yao‐Tseng Chen. Cancer/testis (ct) antigens: potential targets for immunotherapy. Cancer Science, 100(11):2014–2021, October 2009. URL: http://dx.doi.org/10.1111/j.1349-7006.2009.01303.x, doi:10.1111/j.1349-7006.2009.01303.x. This article has 430 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1349-7006.2009.01303.x)

[4. (Ban2020WholeGenome) Yanli Ban, Jean V. Fischer, Kruti P. Maniar, Haiyang Guo, Chang Zeng, Yinuo Li, Qing Zhang, Xinkun Wang, Wei Zhang, Serdar E. Bulun, and Jian-Jun Wei. Whole-genome sequencing and target validation analysis of müllerian adenosarcoma: a tumor with complex but specific genetic alterations. Frontiers in Oncology, April 2020. URL: http://dx.doi.org/10.3389/fonc.2020.00538, doi:10.3389/fonc.2020.00538. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2020.00538)

[5. (Mattila2011NMD) Henna Mattila, Martin Schindler, Jarkko Isotalo, Tarja Ikonen, Mauno Vihinen, Hannu Oja, Teuvo LJ Tammela, Tiina Wahlfors, and Johanna Schleutker. Nmd and microrna expression profiling of the hpcx1 locus reveal magec1 as a candidate prostate cancer predisposition gene. BMC Cancer, August 2011. URL: http://dx.doi.org/10.1186/1471-2407-11-327, doi:10.1186/1471-2407-11-327. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-11-327)